Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.

Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer.

1996 • 708 citations

BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression

1998 • 688 citations

Gene Therapy for Cancer: What Have We Done and Where Are We Going?

1997 • 635 citations

Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression

1995 • 585 citations

Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl

1997 • 509 citations

BRCA1 physically associates with p53 and stimulates its transcriptional activity

1998 • 484 citations

Growth retardation and tumour inhibition by BRCA1

1996 • 360 citations

CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site

1998 • 192 citations

Induction of apoptosis by the tumor suppressor protein BRCA1.

1996 • 140 citations

Human BRCA1 inhibits growth in yeast: Potential use in diagnostic testing

1997 • 106 citations

How large should a phase II trial of a new drug be?

1987 • 96 citations

Cancer-induced immunosuppression: Implications for therapy?

1989 • 66 citations

A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer.

1997 • 66 citations

Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer

1994 • 57 citations

Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response

1996 • 31 citations

ANERGY AND THE SEVERELY ILL SURGICAL PATIENT

1986 • 18 citations

Perioperative Nutritional Support in the Cancer Patient

1986 • 14 citations

Identification of a BRCA1-associated kinase with potential biological relevance

1998 • 13 citations

No stranger to controversy

1997 • 4 citations